Bellevue Group AG
ZURICH, V8
$4.8bn in 148 US stocks at the end of 30 June 2026. The top 10 are 42.9% of the money. It changed about 25.2% of the portfolio this quarter.
Value
$4.8bn
Stocks
148
Top 10 share
42.9%
Turnover
25.2%
What changed this quarter
New
Bought for the first time this quarter.
- Avalyn PharmaAVLN0.9% of the fund
- CG OncologyCGON0.7% of the fund
- Seaport TherapeuticsSPTX0.5% of the fund
- Palvella TherapeuticsPVLA0.5% of the fund
- Spyre TherapeuticsSYRE0.4% of the fund
- Hemab Therapeutics HoldingsCOAG0.4% of the fund
- Parabilis MedicinesPBLS0.3% of the fund
- Aura BiosciencesAURA0.2% of the fund
- Molina HealthcareMOH0.1% of the fund
- GMR SolutionsGMRS0.1% of the fund
- Alamar BiosciencesALMR<0.1% of the fund
- Mobia MedicalMOBI<0.1% of the fund
- VeradermicsMANE<0.1% of the fund
- Definium TherapeuticsDFTX<0.1% of the fund
- ViatrisVTRS<0.1% of the fund
- Cogent BiosciencesCOGT<0.1% of the fund
- WatersWAT<0.1% of the fund
Added
Bought more of a stock they already held.
- AmgenAMGN6.5% of the fund+188%
- Gilead SciencesGILD5.7% of the fund+85%
- Oruka TherapeuticsORKA3.3% of the fund+227%
- InsmedINSM3.1% of the fund+13787%
- VaxcytePCVX2.4% of the fund+66%
- United TherapeuticsUTHR2.1% of the fund+8976%
- BridgeBio PharmaBBIO1.9% of the fund+4587%
- StrykerSYK1.8% of the fund+24%
- MedtronicMDT1.6% of the fund+4%
- DexcomDXCM1.2% of the fund+4%
- Disc MedicineIRON0.9% of the fund+22%
- Thermo Fisher ScientificTMO0.8% of the fund+24%
- Elevance HealthELV0.5% of the fund+7%
- CVS HealthCVS0.4% of the fund+90%
- LivaNovaLIVN0.3% of the fund+5%
- Teva Pharmaceutical IndustriesTEVA0.2% of the fund+38%
- Veeva SystemsVEEV0.2% of the fund+5%
- Protagonist TherapeuticsPTGX0.1% of the fund+285%
- Alkermes plc.ALKS0.1% of the fund+1256%
- Royalty PharmaRPRX0.1% of the fund+193%
- Waystar HoldingWAY0.1% of the fund+15%
- Neurocrine BiosciencesNBIX<0.1% of the fund+417%
- Kestra Medical TechnologiesKMTS<0.1% of the fund+12%
- Beone MedicinesONC<0.1% of the fund+175%
- NewAmsterdam PharmaNAMS<0.1% of the fund+215%
Cut
Sold some of their stake.
- Vertex PharmaceuticalsVRTX6.0% of the fund-15%
- Argenx SEARGX5.9% of the fund-4%
- Revolution MedicinesRVMD4.1% of the fund-32%
- Scholar Rock HoldingSRRK2.8% of the fund-32%
- Relay TherapeuticsRLAY2.4% of the fund-21%
- Intuitive SurgicalISRG2.1% of the fund-11%
- Regeneron PharmaceuticalsREGN2.1% of the fund-44%
- Crinetics PharmaceuticalsCRNX2.1% of the fund-20%
- Abbott LaboratoriesABT1.8% of the fund-18%
- Ionis PharmaceuticalsIONS1.6% of the fund-47%
- Enliven TherapeuticsELVN1.6% of the fund-36%
- Jade BiosciencesJBIO1.4% of the fund-13%
- Edwards LifesciencesEW1.4% of the fund-12%
- Ultragenyx PharmaceuticalRARE1.4% of the fund-17%
- Damora Therapeutics0.9% of the fund-30%
- Boston ScientificBSX0.8% of the fund-39%
- Eli LillyLLY0.8% of the fund-12%
- Idexx LaboratoriesIDXX0.7% of the fund-31%
- ResmedRMD0.6% of the fund-7%
- Krystal BiotechKRYS0.6% of the fund-84%
- Monte Rosa TherapeuticsGLUE0.6% of the fund-5%
- DanaherDHR0.6% of the fund-29%
- Johnson & JohnsonJNJ0.6% of the fund-13%
- AnnexonANNX0.5% of the fund-21%
- HumanaHUM0.5% of the fund-9%
Sold out
Sold their entire stake.
- Edgewise TherapeuticsEWTX-100%
- Inspire Medical SystemsINSP-100%
- PenumbraPEN-100%
- Atrium TherapeuticsRNA-100%
- Masimo-100%
- Equinor ASAEQNR-100%
- ExxonMobil HoldingsXOM-100%
- BPBP-100%
- ShellSHEL-100%
- Cisco SystemsCSCO-100%
- Alibaba Group HldgBABA-100%
- Procter & GamblePG-100%
- MastercardMA-100%
- BlackRockBLK-100%
- VisaV-100%
- Centessa Pharmaceuticals-100%
- Jd.comJD-100%
- AccentureACN-100%
- AdobeADBE-100%
- Olema PharmaceuticalsOLMA-100%
- Ascendis Pharma A/SASND-100%
- BridgeBio Oncology TherapeuticsBBOT-100%
- Wave Life SciencesWVE-100%
- QiagenQGEN-100%
Holdings
- Argenx SEARGX
- Share
- 5.9%
- Value
- $279m
- Shares
- 301,000
-4%
- Nuvalent
- Share
- 2.7%
- Value
- $130m
- Shares
- 1,053,268
Held
- Crinetics PharmaceuticalsCRNX
- Share
- 2.1%
- Value
- $98m
- Shares
- 2,620,000
-20%
- Immunocore HldgsIMCR
- Share
- 1.9%
- Value
- $89m
- Shares
- 2,788,245
Held
- Avalyn PharmaAVLN
- Share
- 0.9%
- Value
- $44m
- Shares
- 1,350,000
New
- Damora Therapeutics
- Share
- 0.9%
- Value
- $42m
- Shares
- 1,618,846
-30%
- Seaport TherapeuticsSPTX
- Share
- 0.5%
- Value
- $24m
- Shares
- 1,100,000
New
- Hemab Therapeutics HoldingsCOAG
- Share
- 0.4%
- Value
- $20m
- Shares
- 550,000
New
- Parabilis MedicinesPBLS
- Share
- 0.3%
- Value
- $14m
- Shares
- 500,000
New
- GMR SolutionsGMRS
- Share
- 0.1%
- Value
- $5m
- Shares
- 333,333
New
- Beone MedicinesONC
- Share
- <0.1%
- Value
- $3m
- Shares
- 10,474
+175%
- State STR Spdr S&P 500 ETF TSPY
- Share
- <0.1%
- Value
- $2m
- Shares
- 2,700
Held
- Biontech SEBNTX
- Share
- <0.1%
- Value
- $2m
- Shares
- 21,229
Held
- Alamar BiosciencesALMR
- Share
- <0.1%
- Value
- $2m
- Shares
- 55,738
New
- Mobia MedicalMOBI
- Share
- <0.1%
- Value
- $1m
- Shares
- 100,000
New
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| AmgenAMGN | 6.5% | $308m | 851,550 | +188% |
| Vertex PharmaceuticalsVRTX | 6.0% | $287m | 578,634 | -15% |
| Argenx SEARGX | 5.9% | $279m | 301,000 | -4% |
| Gilead SciencesGILD | 5.7% | $273m | 2,158,772 | +85% |
| Revolution MedicinesRVMD | 4.1% | $196m | 1,048,014 | -32% |
| Oruka TherapeuticsORKA | 3.3% | $158m | 1,657,190 | +227% |
| InsmedINSM | 3.1% | $149m | 1,393,418 | +13787% |
| Scholar Rock HoldingSRRK | 2.8% | $135m | 2,449,547 | -32% |
| Nuvalent | 2.7% | $130m | 1,053,268 | Held |
| Viridian TherapeuticsVRDN | 2.6% | $124m | 6,731,909 | Held |
| Relay TherapeuticsRLAY | 2.4% | $116m | 6,185,970 | -21% |
| VaxcytePCVX | 2.4% | $115m | 1,971,935 | +66% |
| United TherapeuticsUTHR | 2.1% | $102m | 188,515 | +8976% |
| Intuitive SurgicalISRG | 2.1% | $101m | 254,809 | -11% |
| Regeneron PharmaceuticalsREGN | 2.1% | $98m | 157,291 | -44% |
| Crinetics PharmaceuticalsCRNX | 2.1% | $98m | 2,620,000 | -20% |
| BridgeBio PharmaBBIO | 1.9% | $89m | 1,189,506 | +4587% |
| Immunocore HldgsIMCR | 1.9% | $89m | 2,788,245 | Held |
| Abbott LaboratoriesABT | 1.8% | $86m | 947,115 | -18% |
| StrykerSYK | 1.8% | $85m | 268,461 | +24% |
| MedtronicMDT | 1.6% | $78m | 994,233 | +4% |
| Ionis PharmaceuticalsIONS | 1.6% | $77m | 972,258 | -47% |
| Enliven TherapeuticsELVN | 1.6% | $76m | 1,490,000 | -36% |
| Vera TherapeuticsVERA | 1.5% | $73m | 1,710,808 | Held |
| Jade BiosciencesJBIO | 1.4% | $68m | 3,057,996 | -13% |
| Edwards LifesciencesEW | 1.4% | $67m | 739,234 | -12% |
| Ultragenyx PharmaceuticalRARE | 1.4% | $66m | 1,982,775 | -17% |
| UnitedHealth GroupUNH | 1.3% | $62m | 149,127 | Held |
| DexcomDXCM | 1.2% | $55m | 822,489 | +4% |
| Celldex TherapeuticsCLDX | 0.9% | $45m | 1,200,000 | Held |
| Avalyn PharmaAVLN | 0.9% | $44m | 1,350,000 | New |
| Damora Therapeutics | 0.9% | $42m | 1,618,846 | -30% |
| Disc MedicineIRON | 0.9% | $41m | 560,000 | +22% |
| Thermo Fisher ScientificTMO | 0.8% | $40m | 79,816 | +24% |
| Boston ScientificBSX | 0.8% | $38m | 887,650 | -39% |
| Eli LillyLLY | 0.8% | $36m | 29,882 | -12% |
| CG OncologyCGON | 0.7% | $35m | 493,596 | New |
| Idexx LaboratoriesIDXX | 0.7% | $33m | 61,780 | -31% |
| ResmedRMD | 0.6% | $29m | 148,195 | -7% |
| Krystal BiotechKRYS | 0.6% | $29m | 77,530 | -84% |
| Monte Rosa TherapeuticsGLUE | 0.6% | $29m | 1,190,000 | -5% |
| DanaherDHR | 0.6% | $27m | 143,844 | -29% |
| Johnson & JohnsonJNJ | 0.6% | $26m | 103,280 | -13% |
| Seaport TherapeuticsSPTX | 0.5% | $24m | 1,100,000 | New |
| Palvella TherapeuticsPVLA | 0.5% | $24m | 155,000 | New |
| Align TechnologyALGN | 0.5% | $24m | 139,680 | Held |
| AnnexonANNX | 0.5% | $23m | 4,100,016 | -21% |
| HumanaHUM | 0.5% | $23m | 58,398 | -9% |
| Elevance HealthELV | 0.5% | $22m | 56,449 | +7% |
| Tango TherapeuticsTNGX | 0.5% | $22m | 694,182 | -71% |
| SterisSTE | 0.4% | $21m | 99,877 | Held |
| Spyre TherapeuticsSYRE | 0.4% | $20m | 229,931 | New |
| Hemab Therapeutics HoldingsCOAG | 0.4% | $20m | 550,000 | New |
| InsuletPODD | 0.4% | $19m | 127,498 | -22% |
| Cigna GroupCI | 0.4% | $18m | 66,500 | -32% |
| GlaukosGKOS | 0.4% | $18m | 128,667 | -12% |
| CVS HealthCVS | 0.4% | $18m | 169,366 | +90% |
| Becton DickinsonBDX | 0.3% | $17m | 109,729 | -10% |
| GE HealthCare TechnologiesGEHC | 0.3% | $16m | 252,744 | -39% |
| LivaNovaLIVN | 0.3% | $16m | 195,621 | +5% |
| CenteneCNC | 0.3% | $15m | 228,865 | -12% |
| MerckMRK | 0.3% | $15m | 113,061 | -45% |
| Cooper CompaniesCOO | 0.3% | $14m | 197,135 | -28% |
| Parabilis MedicinesPBLS | 0.3% | $14m | 500,000 | New |
| Teva Pharmaceutical IndustriesTEVA | 0.2% | $12m | 345,899 | +38% |
| Globus MedicalGMED | 0.2% | $12m | 146,108 | -41% |
| PROCEPT BioRoboticsPRCT | 0.2% | $11m | 502,286 | Held |
| Zimmer Biomet HoldingsZBH | 0.2% | $11m | 126,707 | -19% |
| Veeva SystemsVEEV | 0.2% | $11m | 59,347 | +5% |
| AbbVieABBV | 0.2% | $10m | 40,476 | -57% |
| 10x GenomicsTXG | 0.2% | $10m | 261,470 | -21% |
| HCA HealthcareHCA | 0.2% | $9m | 23,750 | -37% |
| Aura BiosciencesAURA | 0.2% | $8m | 1,166,667 | New |
| MckessonMCK | 0.2% | $7m | 9,625 | -57% |
| Tenet HealthcareTHC | 0.2% | $7m | 38,868 | Held |
| Protagonist TherapeuticsPTGX | 0.1% | $7m | 55,682 | +285% |
| NateraNTRA | 0.1% | $7m | 24,806 | -22% |
| TransMedics GroupTMDX | 0.1% | $7m | 101,139 | Held |
| Molina HealthcareMOH | 0.1% | $6m | 27,761 | New |
| Alkermes plc.ALKS | 0.1% | $6m | 120,243 | +1256% |
| Royalty PharmaRPRX | 0.1% | $6m | 112,311 | +193% |
| Waystar HoldingWAY | 0.1% | $6m | 293,592 | +15% |
| Privia Health GroupPRVA | 0.1% | $6m | 226,703 | Held |
| GMR SolutionsGMRS | 0.1% | $5m | 333,333 | New |
| Neurocrine BiosciencesNBIX | <0.1% | $4m | 24,037 | +417% |
| Omada HealthOMDA | <0.1% | $3m | 157,938 | Held |
| Kestra Medical TechnologiesKMTS | <0.1% | $3m | 129,215 | +12% |
| MedlineMDLN | <0.1% | $3m | 82,153 | -40% |
| IlluminaILMN | <0.1% | $3m | 18,134 | -10% |
| Beone MedicinesONC | <0.1% | $3m | 10,474 | +175% |
| NewAmsterdam PharmaNAMS | <0.1% | $3m | 86,994 | +215% |
| Madrigal PharmaceuticalsMDGL | <0.1% | $3m | 4,675 | +54% |
| State STR Spdr S&P 500 ETF TSPY | <0.1% | $2m | 2,700 | Held |
| Biontech SEBNTX | <0.1% | $2m | 21,229 | Held |
| Adaptive BiotechnologiesADPT | <0.1% | $2m | 89,439 | +17% |
| CytokineticsCYTK | <0.1% | $2m | 19,007 | +115% |
| Alamar BiosciencesALMR | <0.1% | $2m | 55,738 | New |
| PhreesiaPHR | <0.1% | $1m | 140,495 | +7% |
| Mobia MedicalMOBI | <0.1% | $1m | 100,000 | New |
| BillionToOneBLLN | <0.1% | $1m | 10,554 | Held |
Showing the largest 100 of 148.
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 4.7% since 30 June 2025.
Where the money is
Health care88.1%
Technology0.2%
Industrials0.1%
Retail & consumer0.0%
Media & telecom0.0%
Other11.6%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.